Upadoz 15 mg

About Upadoz 15 mg

Upadacitinib is an oral Janus kinase (JAK) inhibitor that may be used alone or in combination with other medications to treat several conditions that have inflammation as a characteristic symptom. It works by decreasing the activity of the immune system. Upadacitinib may also be used to treat:

rheumatoid arthritis in people who are unable to take or have not responded well to one or more tumor necrosis factor (TNF) inhibitor medication(s)

psoriatic arthritis (a condition that causes joint pain and swelling, and scales on the skin) in adults who are unable to take or did not respond to or tolerate one or more TNF inhibitor medication(s)

symptoms of eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children 12 years and older who cannot use other medications for their condition or whose eczema has not responded to other medications

ulcerative colitis (a condition that causes swelling and sores in the lining of the colon [large intestine] and rectum) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s)

Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) in adults who cannot take or who did not respond to one or more TNF inhibitor medication(s)

Giant cell arteritis (an inflammatory condition of the temporal arteries) in adults.

Upadacitinib is used to treat ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas, causing pain, swelling, and joint damage) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s).

Other conditions that upadacitinib may be used to treat include:

active non-radiographic axial spondyloarthritis (a condition in which the body attacks the joints of the spine and other areas, causing pain and signs of swelling), but without changes seen on X-ray, in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s)

active polyarticular juvenile idiopathic arthritis in children aged 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers.

There are two formulations of upadacitinib: Rinvoq extended-release tablets and Rinvoq LQ liquid solution. These two formulations are not interchangeable.

Upadacitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.